---
provider: falcon
model: Edison Scientific Literature
cached: true
start_time: '2026-02-14T10:37:06.557355'
end_time: '2026-02-14T10:37:06.559130'
duration_seconds: 0.0
template_file: templates/disease_pathophysiology_research.md
template_variables:
  disease_name: Fanconi Anemia
  mondo_id: ''
  category: Genetic
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 28
---

## Question

# Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Fanconi Anemia
- **MONDO ID:**  (if available)
- **Category:** Genetic

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Fanconi Anemia**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs


## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Fanconi Anemia
- **MONDO ID:**  (if available)
- **Category:** Genetic

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Fanconi Anemia**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs


# Disease Pathophysiology Research Report

## Target Disease
- Disease Name: Fanconi Anemia (FA)
- MONDO ID: MONDO:0019391
- Category: Genetic (DNA repair disorder)

## Pathophysiology Description (Narrative)
Fanconi anemia is a genomic instability syndrome caused by biallelic pathogenic variants in genes encoding the FA/BRCA DNA interstrand crosslink (ICL) repair pathway. The central biochemical lesion is the DNA ICL, which stalls replication and transcription, provoking replication fork collapse, chromosomal breakage, and activation of checkpoint signaling. The FA core complex (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, plus FAAPs) recognizes ICL-stalled forks and catalyzes the monoubiquitination of the FANCD2–FANCI (I-D2) complex via the E3 ligase FANCL and the E2 UBE2T (FANCT). Monoubiquitinated I-D2 localizes to damaged chromatin and orchestrates nuclease-mediated “unhooking” (e.g., SLX4/FANCP scaffolding XPF–ERCC1 and SLX1), translesion synthesis (TLS, Polζ with FANCV/REV7), and homologous recombination (HR) to complete repair; the cycle is reset by USP1-mediated deubiquitination. FA proteins also protect stressed forks, interface with ATR/CHK1 signaling, and contribute to mitotic integrity (ultrafine bridges), explaining the broad chromosomal instability and cancer predisposition in FA (URL: https://doi.org/10.1182/blood-2014-04-526293; Oct 2014) (longerich2014stressanddna pages 4-5, longerich2014stressanddna pages 7-8). Recent work further shows that PCNA monoubiquitination at K164 is critical to canalize ICL repair toward canonical FA/TLS: in its absence, MSH2–MSH6 mismatch repair is mis-recruited to ICLs, and combined PcnaK164R and FA deficiency is embryonic lethal, highlighting a dual role of PCNA-Ub in polymerase switching and pathway choice (URL: https://doi.org/10.1093/pnasnexus/pgae242; Jun 2024) (shah2024dualroleof pages 1-2).

Endogenous aldehydes are major physiological sources of crosslinking and DNA–protein crosslink damage in hematopoietic stem cells (HSCs). A two-tier protection model has emerged: tier-1 detoxification by ADH5 (formaldehyde) and ALDH2 (acetaldehyde), and tier-2 removal of aldehyde-induced lesions by the FA repair pathway. In humans with FA, the dominant-negative ALDH2*2 variant accelerates progression of bone marrow failure, underscoring aldehyde burden as a disease modifier and therapeutic target (URL: https://doi.org/10.1182/blood-2013-06-507962; Oct 2013) (hira2013variantaldh2is pages 1-2). Reviews and mechanistic syntheses concur that aldehyde genotoxicity, replication stress with ATR activation, and chronic inflammatory/oxidative milieus converge to drive HSC attrition, myelodysplasia/AML, and squamous carcinogenesis (URLs: https://doi.org/10.3390/ijms252111619; Oct 2024; https://doi.org/10.1146/annurev-pathmechdis-111523-023420; Jan 2025; https://doi.org/10.1186/s13023-025-03896-w; Jul 2025) (repczynska2024newinsightsinto pages 9-13, repczynska2024newinsightsinto pages 13-17, liu2025inheritedpredispositionsto pages 13-15, fang2025comprehensivereviewon pages 1-3).

Two 2024 advances refine FA pathophysiology and therapeutic angles: (1) fetal HSC failure originates in the fetal liver from inflammation-driven ER stress and proteostasis disruption in LT-HSCs; restoring protein folding with the chemical chaperone TUDCA and dampening type I interferon signaling rescue fetal Fancd2−/− LT-HSC pool size, identifying proteostasis/inflammation as actionable nodes (URL: https://doi.org/10.1038/s41467-024-46159-1; Feb 2024) (kovuru2024deregulatedproteinhomeostasis pages 10-11). (2) In head and neck squamous cell carcinoma (HNSCC), KMT2D loss increases glycolysis and, under glycolytic inhibition, epigenetically suppresses FA/BRCA gene expression by converting FA gene promoters/enhancers to inactive states; combining 2-deoxyglucose with DNA crosslinkers or PARP inhibitors preferentially suppresses KMT2D-deficient tumors, linking metabolic state, chromatin, and FA pathway competence (URL: https://doi.org/10.1038/s41467-024-50861-5; Aug 2024) (liu2024histonemethyltransferasekmt2ddeficiency pages 1-2).

## 1. Core Pathophysiology
- Primary mechanisms: Defective ICL repair at stalled replication forks with failure of FANCD2–FANCI monoubiquitination dynamics, aberrant nuclease unhooking, faulty TLS, and impaired HR. Consequences include replication fork collapse, chromosomal breakage, anaphase bridge formation, and checkpoint activation defects (URLs: 2014 Blood review; 2025 Annual Review) (longerich2014stressanddna pages 4-5, longerich2014stressanddna pages 7-8, liu2025inheritedpredispositionsto pages 13-15).
- Dysregulated molecular pathways: FA/BRCA ICL repair axis; ATR/ATM–CHK1 signaling coupling to FANCI phosphorylation and FANCD2 activity; PCNA-Ub-dependent damage tolerance steering TLS vs. MMR at ICLs (URL: 2024 PNAS Nexus) (longerich2014stressanddna pages 7-8, shah2024dualroleof pages 1-2).
- Affected cellular processes: HSC quiescence maintenance fails under chronic replication stress and inflammatory ROS; mitotic integrity is compromised (ultrafine bridges/cytokinesis failure), leading to clonal evolution (URLs: 2014 Blood; 2025 Annual Review) (longerich2014stressanddna pages 7-8, liu2025inheritedpredispositionsto pages 13-15).

## 2. Key Molecular Players
- Genes/Proteins (HGNC):
  - FA core and I-D2: FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FANCM, UBE2T (FANCT), FANCD2, FANCI; E3 ligase–E2 module FANCL–UBE2T (URLs: 2014 Blood; 2024 IJMS review) (longerich2014stressanddna pages 4-5, repczynska2024newinsightsinto pages 9-13).
  - Nucleases/scaffold: SLX4/FANCP, XPF–ERCC1, SLX1; FAN1 recruits to Ub-FANCD2 (URL: 2014 Blood) (longerich2014stressanddna pages 4-5).
  - TLS: REV1, POLζ (REV3L/REV7 [FANCV]); PCNA-Ub; RAD6–RAD18 (URL: 2024 PNAS Nexus) (shah2024dualroleof pages 1-2).
  - HR: BRCA2/FANCD1, PALB2/FANCN, BRCA1/FANCS, RAD51/RAD51C (FANCO), XRCC2 (FANCU), RFWD3 (URLs: 2024 IJMS review; 2025 Annual Review) (repczynska2024newinsightsinto pages 9-13, liu2025inheritedpredispositionsto pages 13-15).
  - Signaling: ATR–ATRIP, CHK1; FANCI phosphorylation “switch” (URL: 2014 Blood) (longerich2014stressanddna pages 7-8).
  - Aldehyde detoxification: ALDH2, ADH5 (URL: 2013 Blood) (hira2013variantaldh2is pages 1-2).
  - Epigenetic-metabolic regulator in SCC: KMT2D (H3K4 methyltransferase) modulating FA gene chromatin under glycolytic stress (URL: 2024 Nat Commun) (liu2024histonemethyltransferasekmt2ddeficiency pages 1-2).
- Chemical Entities (CHEBI): acetaldehyde (CHEBI:15343), formaldehyde (CHEBI:16842); mitomycin C (CHEBI:50684), diepoxybutane (CHEBI:42680); 2-deoxy-D-glucose (CHEBI:17698); tauroursodeoxycholic acid (TUDCA; bile acid derivative, CHEBI:132954) (hira2013variantaldh2is pages 1-2, liu2024histonemethyltransferasekmt2ddeficiency pages 1-2, kovuru2024deregulatedproteinhomeostasis pages 10-11).
- Cell Types (CL): long-term hematopoietic stem cells (LT-HSCs; CL:0000037), hematopoietic progenitors (CL:0000038), mesenchymal stromal cells (CL:0000134); inflammatory macrophages/Kupffer cells (CL:0000706) are implicated as niche sources of sterile inflammation in fetal liver (kovuru2024deregulatedproteinhomeostasis pages 10-11).
- Anatomical Locations (UBERON): bone marrow (UBERON:0002371); fetal liver (UBERON:0002107); oral cavity mucosa (UBERON:0001729) and esophagus (UBERON:0001043) as SCC sites (fang2025comprehensivereviewon pages 1-3).

## 3. Biological Processes (GO terms; disrupted in FA)
- DNA interstrand cross-link repair (GO:0036297): core FA/BRCA function (longerich2014stressanddna pages 4-5, liu2025inheritedpredispositionsto pages 13-15).
- DNA damage tolerance via translesion synthesis (GO:0043085) and PCNA monoubiquitination (GO:0008630 for DNA damage response ubiquitination): pathway choice at ICLs (shah2024dualroleof pages 1-2).
- DNA double-strand break repair via homologous recombination (GO:0000724): post-unhooking repair (longerich2014stressanddna pages 4-5, liu2025inheritedpredispositionsto pages 13-15).
- ATR signaling pathway (GO:0038061) and checkpoint signaling (GO:0000077): coupling to FANCI/FANCD2 (longerich2014stressanddna pages 7-8).
- Response to aldehyde (GO:0043437) and detoxification (GO:0098754): ADH5/ALDH2 tier-1 protection (hira2013variantaldh2is pages 1-2, repczynska2024newinsightsinto pages 13-17).
- Cellular response to oxidative stress (GO:0034599) and ER stress/protein folding (GO:0034976; GO:0006457): fetal HSC proteostasis defect (kovuru2024deregulatedproteinhomeostasis pages 10-11, repczynska2024newinsightsinto pages 9-13).
- Regulation of chromosomal stability/mitotic cytokinesis (e.g., chromosome segregation GO:0007059): ultrafine bridges in FA (longerich2014stressanddna pages 4-5).

## 4. Cellular Components (GO CC)
- Nuclear chromatin and replication forks: site of I-D2 accumulation and nuclease/TLS assembly (longerich2014stressanddna pages 4-5).
- FA core complex at chromatin; PCNA at replication foci (shah2024dualroleof pages 1-2).
- Endoplasmic reticulum: site of proteostasis stress in fetal FA LT-HSCs (kovuru2024deregulatedproteinhomeostasis pages 10-11).

## 5. Disease Progression (Sequence of events)
1) Initiating lesions: endogenous aldehydes (acetaldehyde/formaldehyde) and oxidative metabolism generate ICLs and DPCs in HSCs; detoxification capacity (ALDH2/ADH5) modulates burden (human ALDH2*2 accelerates BMF) (hira2013variantaldh2is pages 1-2, repczynska2024newinsightsinto pages 13-17).
2) Repair failure at replication: defective FA core recruitment and I-D2 monoubiquitination limit nuclease unhooking, TLS insertion across unhooked adduct, and HR-mediated restoration; ATR/CHK signaling becomes chronically engaged (longerich2014stressanddna pages 4-5, longerich2014stressanddna pages 7-8, liu2025inheritedpredispositionsto pages 13-15).
3) Cellular outcomes: fork collapse, chromosomal breakage, mitotic bridge formation; TP53 activation and apoptotic attrition of HSCs; chronic ROS/inflammatory signaling exacerbate senescence and HSC pool depletion (longerich2014stressanddna pages 7-8, liu2025inheritedpredispositionsto pages 13-15, repczynska2024newinsightsinto pages 9-13).
4) Developmental window: fetal liver LT-HSCs are particularly vulnerable due to inflammation-driven ER stress and proteostasis breakdown; TUDCA and type I interferon dampening rescue fetal LT-HSC numbers in Fancd2−/− (kovuru2024deregulatedproteinhomeostasis pages 10-11).
5) Malignant evolution: persistent genomic instability and replication stress select for clones tolerating checkpoints, predisposing to MDS/AML and early-onset squamous cell carcinomas of the oral/anogenital/upper aerodigestive tract (liu2025inheritedpredispositionsto pages 13-15, fang2025comprehensivereviewon pages 1-3).

## 6. Phenotypic Manifestations (Mechanism links)
- Progressive bone marrow failure with pancytopenia (HP:0001873) from HSC attrition driven by repair failure, aldehyde genotoxicity, and inflammatory/proteostatic stress (hira2013variantaldh2is pages 1-2, kovuru2024deregulatedproteinhomeostasis pages 10-11, liu2025inheritedpredispositionsto pages 13-15).
- Congenital anomalies (e.g., radial ray defects, renal anomalies) linked to developmental replication stress and checkpoint perturbations (fang2025comprehensivereviewon pages 1-3).
- Cancer predisposition: markedly elevated risk and early onset of squamous cell carcinomas (oral, anogenital, esophageal) and MDS/AML due to chronic chromosomal instability and replication stress; oral surveillance is emphasized in clinical guidance (fang2025comprehensivereviewon pages 1-3, repczynska2024newinsightsinto pages 9-13).

## Current Applications and Real-World Implementations
- Diagnostic: DEB/MMC chromosomal breakage assays and FANCD2 monoubiquitination readouts to functionally assess FA pathway competence; NGS panels to genotype FA genes (fang2025comprehensivereviewon pages 1-3).
- Risk modification: counseling on aldehyde exposures (ethanol); consideration of ALDH2 genotype as a modifier of hematologic risk in FA (hira2013variantaldh2is pages 1-2).
- Transplant: HSCT for marrow failure, with continued cancer surveillance due to persistent epithelial cancer risk (repczynska2024newinsightsinto pages 9-13).
- Emerging targeted strategies: metabolic–epigenetic targeting in KMT2D-deficient HNSCC to reduce FA/BRCA gene expression and sensitize to DNA crosslinkers/PARP inhibitors (preclinical) (liu2024histonemethyltransferasekmt2ddeficiency pages 1-2); fetal-stage interventions aimed at proteostasis and interferon tone (TUDCA; IFN signaling) to preserve HSC pools (preclinical) (kovuru2024deregulatedproteinhomeostasis pages 10-11); pathway steering via PCNA-Ub to avoid MMR engagement at ICLs suggests opportunities to modulate damage tolerance (shah2024dualroleof pages 1-2).

## Expert Opinions and Analysis (Authoritative sources)
- Authoritative reviews conclude that FA is best understood as a failure of the ICL repair network at the replication fork, integrated with ATR checkpoint signaling and with broad mitotic consequences, unifying marrow failure and carcinogenesis (Blood 2014; Annual Review of Pathology 2025) (longerich2014stressanddna pages 4-5, longerich2014stressanddna pages 7-8, liu2025inheritedpredispositionsto pages 13-15).
- The aldehyde two-tier model has strong genetic and human evidence; ALDH2*2 in FA patients provides clinical validation of aldehyde-driven pathogenesis (Blood 2013) (hira2013variantaldh2is pages 1-2).
- 2024–2025 updates emphasize systems-level crosstalk: fetal inflammatory–proteostasis stress as the origin of HSC pool deficits; and metabolic–epigenetic regulation of FA gene expression in SCC, revealing disease stage-/context-specific therapeutic opportunities (Nat Commun 2024; PNAS Nexus 2024) (kovuru2024deregulatedproteinhomeostasis pages 10-11, liu2024histonemethyltransferasekmt2ddeficiency pages 1-2, shah2024dualroleof pages 1-2).

## Relevant Statistics and Data (recent)
- Early-onset epithelial cancer risk in FA: elevated oral/anogenital SCC incidence with young median onset; clinical management emphasizes early detection and surgical management (URL: https://doi.org/10.1186/s13023-025-03896-w; Jul 2025) (fang2025comprehensivereviewon pages 1-3).
- Human genetic modifier: ALDH2*2 carriers among Japanese FA patients exhibit significantly faster progression to bone marrow failure relative to noncarriers (URL: https://doi.org/10.1182/blood-2013-06-507962; Oct 2013) (hira2013variantaldh2is pages 1-2).

## Gene/Protein Annotations (selected; HGNC with key roles)
- FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL (core complex; E3 ligase function via FANCL); UBE2T (FANCT; E2); FANCD2, FANCI (I-D2 complex); FANCM (fork sensor/translocase); SLX4/FANCP (nuclease scaffold); XPF–ERCC1, SLX1 (unhooking); REV7/FANCV, REV3L (Polζ TLS); BRCA2/FANCD1, PALB2/FANCN, BRCA1/FANCS, RAD51 family (HR). Evidence: 2014 Blood; 2024 IJMS; 2025 Annual Review (longerich2014stressanddna pages 4-5, repczynska2024newinsightsinto pages 9-13, liu2025inheritedpredispositionsto pages 13-15).

## Phenotype Associations (HP terms)
- Bone marrow failure/pancytopenia (HP:0001873), Aplastic anemia (HP:0001903) (liu2025inheritedpredispositionsto pages 13-15).
- Squamous cell carcinoma (HP:0002860) of oral cavity/anogenital tract; early onset (fang2025comprehensivereviewon pages 1-3, repczynska2024newinsightsinto pages 9-13).
- Congenital limb anomalies (e.g., radial ray malformations; HP:0002986) (fang2025comprehensivereviewon pages 1-3).

## Cell Type Involvement (CL terms)
- Long-term HSCs (CL:0000037) and HSPCs: replication stress sensitivity, aldehyde damage, inflammatory/ER stress in fetal liver (kovuru2024deregulatedproteinhomeostasis pages 10-11, liu2025inheritedpredispositionsto pages 13-15).
- Mesenchymal stromal cells (CL:0000134): niche contributions are under investigation (repczynska2024newinsightsinto pages 9-13).

## Anatomical Locations (UBERON)
- Bone marrow (UBERON:0002371), fetal liver (UBERON:0002107), oral cavity (UBERON:0001729), esophagus (UBERON:0001043) (fang2025comprehensivereviewon pages 1-3, kovuru2024deregulatedproteinhomeostasis pages 10-11).

## Chemical Entities (CHEBI)
- Acetaldehyde (CHEBI:15343), formaldehyde (CHEBI:16842): endogenous aldehydes driving lesions (hira2013variantaldh2is pages 1-2, repczynska2024newinsightsinto pages 13-17).
- 2-deoxy-D-glucose (CHEBI:17698): glycolysis inhibitor revealing FA gene epigenomic dependency in KMT2D-deficient SCC (liu2024histonemethyltransferasekmt2ddeficiency pages 1-2).
- Tauroursodeoxycholic acid, TUDCA (CHEBI:132954): chemical chaperone rescuing fetal Fancd2−/− LT-HSCs (kovuru2024deregulatedproteinhomeostasis pages 10-11).

## Evidence Items (PMIDs/DOIs, URLs, dates)
- Stress and DNA repair biology of the FA pathway (mechanistic core; Blood 2014): DOI 10.1182/blood-2014-04-526293; URL: https://doi.org/10.1182/blood-2014-04-526293; Oct 2014 (longerich2014stressanddna pages 4-5, longerich2014stressanddna pages 7-8).
- New insights: inflammation/oxidative stress crosstalk in FA (IJMS 2024): DOI 10.3390/ijms252111619; URL: https://doi.org/10.3390/ijms252111619; Oct 2024 (repczynska2024newinsightsinto pages 9-13, repczynska2024newinsightsinto pages 13-17).
- Inherited predispositions to myeloid neoplasms (FA overview; Annu Rev Pathol 2025): DOI 10.1146/annurev-pathmechdis-111523-023420; URL: https://doi.org/10.1146/annurev-pathmechdis-111523-023420; Jan 2025 (liu2025inheritedpredispositionsto pages 13-15).
- ALDH2 variant accelerates BMF in Japanese FA (Blood 2013): DOI 10.1182/blood-2013-06-507962; URL: https://doi.org/10.1182/blood-2013-06-507962; Oct 2013 (hira2013variantaldh2is pages 1-2).
- Comprehensive FA review with tumor focus (Orphanet J Rare Dis 2025): DOI 10.1186/s13023-025-03896-w; URL: https://doi.org/10.1186/s13023-025-03896-w; Jul 2025 (fang2025comprehensivereviewon pages 1-3).
- PCNA monoubiquitination governs FA-mediated ICL repair and excludes MMR (PNAS Nexus 2024): DOI 10.1093/pnasnexus/pgae242; URL: https://doi.org/10.1093/pnasnexus/pgae242; Jun 2024 (shah2024dualroleof pages 1-2).
- Fetal FA LT-HSC proteostasis/ER stress and TUDCA rescue (Nat Commun 2024): DOI 10.1038/s41467-024-46159-1; URL: https://doi.org/10.1038/s41467-024-46159-1; Feb 2024 (kovuru2024deregulatedproteinhomeostasis pages 10-11).
- DNA repair–metabolism crosstalk in HSCs (Cells 2024): DOI 10.3390/cells13090733; URL: https://doi.org/10.3390/cells13090733; Apr 2024 (xu2024crosstalkbetweendna pages 7-9).
- KMT2D deficiency, glycolysis, and FA/BRCA gene repression in SCC (Nat Commun 2024): DOI 10.1038/s41467-024-50861-5; URL: https://doi.org/10.1038/s41467-024-50861-5; Aug 2024 (liu2024histonemethyltransferasekmt2ddeficiency pages 1-2).

## Concluding Remarks
FA pathogenesis is anchored in defective ICL repair at the replication fork, compounded by endogenous aldehyde genotoxicity, replication stress/ATR signaling, and context-specific inflammatory and metabolic stresses in hematopoietic and epithelial compartments. 2023–2024 research adds mechanistic layers: fetal liver proteostasis–interferon circuits driving LT-HSC loss and an epigenetic–metabolic axis that tunes FA gene expression and therapeutic response in SCC. Together, these advances refine targets for intervention—detoxification/alcohol counseling, fetal-stage proteostasis/innate immune modulation, and tumor-context metabolic–epigenetic therapies—while preserving the centrality of the FA/BRCA repair pathway in both marrow failure and cancer risk (longerich2014stressanddna pages 4-5, hira2013variantaldh2is pages 1-2, kovuru2024deregulatedproteinhomeostasis pages 10-11, liu2024histonemethyltransferasekmt2ddeficiency pages 1-2).

References

1. (longerich2014stressanddna pages 4-5): Simonne Longerich, Jian Li, Yong Xiong, Patrick Sung, and Gary M. Kupfer. Stress and dna repair biology of the fanconi anemia pathway. Blood, 124 18:2812-9, Oct 2014. URL: https://doi.org/10.1182/blood-2014-04-526293, doi:10.1182/blood-2014-04-526293. This article has 106 citations and is from a highest quality peer-reviewed journal.

2. (longerich2014stressanddna pages 7-8): Simonne Longerich, Jian Li, Yong Xiong, Patrick Sung, and Gary M. Kupfer. Stress and dna repair biology of the fanconi anemia pathway. Blood, 124 18:2812-9, Oct 2014. URL: https://doi.org/10.1182/blood-2014-04-526293, doi:10.1182/blood-2014-04-526293. This article has 106 citations and is from a highest quality peer-reviewed journal.

3. (shah2024dualroleof pages 1-2): Ronak Shah, Muhammad Assad Aslam, Aldo Spanjaard, Daniel de Groot, Lisa M Zürcher, Maarten Altelaar, Liesbeth Hoekman, Colin E J Pritchard, Bas Pilzecker, Paul C M van den Berk, and Heinz Jacobs. Dual role of proliferating cell nuclear antigen monoubiquitination in facilitating fanconi anemia-mediated interstrand crosslink repair. PNAS Nexus, Jun 2024. URL: https://doi.org/10.1093/pnasnexus/pgae242, doi:10.1093/pnasnexus/pgae242. This article has 0 citations and is from a peer-reviewed journal.

4. (hira2013variantaldh2is pages 1-2): Asuka Hira, Hiromasa Yabe, Kenichi Yoshida, Yusuke Okuno, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Satoru Miyano, Jun Nakamura, Seiji Kojima, Seishi Ogawa, Keitaro Matsuo, Minoru Takata, and Miharu Yabe. Variant aldh2 is associated with accelerated progression of bone marrow failure in japanese fanconi anemia patients. Blood, 122 18:3206-9, Oct 2013. URL: https://doi.org/10.1182/blood-2013-06-507962, doi:10.1182/blood-2013-06-507962. This article has 213 citations and is from a highest quality peer-reviewed journal.

5. (repczynska2024newinsightsinto pages 9-13): Anna Repczynska, Barbara Ciastek, and Olga Haus. New insights into the fanconi anemia pathogenesis: a crosstalk between inflammation and oxidative stress. International Journal of Molecular Sciences, 25:11619, Oct 2024. URL: https://doi.org/10.3390/ijms252111619, doi:10.3390/ijms252111619. This article has 5 citations and is from a poor quality or predatory journal.

6. (repczynska2024newinsightsinto pages 13-17): Anna Repczynska, Barbara Ciastek, and Olga Haus. New insights into the fanconi anemia pathogenesis: a crosstalk between inflammation and oxidative stress. International Journal of Molecular Sciences, 25:11619, Oct 2024. URL: https://doi.org/10.3390/ijms252111619, doi:10.3390/ijms252111619. This article has 5 citations and is from a poor quality or predatory journal.

7. (liu2025inheritedpredispositionsto pages 13-15): Yen-Chun Liu, Mohammad K. Eldomery, Jamie L. Maciaszek, and Jeffery M. Klco. Inherited predispositions to myeloid neoplasms: pathogenesis and clinical implications. Annual Review of Pathology: Mechanisms of Disease, 20:87-114, Jan 2025. URL: https://doi.org/10.1146/annurev-pathmechdis-111523-023420, doi:10.1146/annurev-pathmechdis-111523-023420. This article has 7 citations and is from a domain leading peer-reviewed journal.

8. (fang2025comprehensivereviewon pages 1-3): Chenyan Fang, Zhoujun Zhu, Jun Cao, Jun Huang, and Yipeng Xu. Comprehensive review on fanconi anemia: insights into dna interstrand cross-links, repair pathways, and associated tumors. Orphanet Journal of Rare Diseases, Jul 2025. URL: https://doi.org/10.1186/s13023-025-03896-w, doi:10.1186/s13023-025-03896-w. This article has 4 citations and is from a peer-reviewed journal.

9. (kovuru2024deregulatedproteinhomeostasis pages 10-11): Narasaiah Kovuru, Makiko Mochizuki-Kashio, Theresa Menna, Greer Jeffrey, Yuning Hong, Young me Yoon, Zhe Zhang, and Peter Kurre. Deregulated protein homeostasis constrains fetal hematopoietic stem cell pool expansion in fanconi anemia. Nature Communications, Feb 2024. URL: https://doi.org/10.1038/s41467-024-46159-1, doi:10.1038/s41467-024-46159-1. This article has 7 citations and is from a highest quality peer-reviewed journal.

10. (liu2024histonemethyltransferasekmt2ddeficiency pages 1-2): Wei Liu, Hongchao Cao, Jing Wang, Areeg Elmusrati, Bing Han, Wei Chen, Ping Zhou, Xiyao Li, Stephen Keysar, Antonio Jimeno, and Cun-Yu Wang. Histone-methyltransferase kmt2d deficiency impairs the fanconi anemia/brca pathway upon glycolytic inhibition in squamous cell carcinoma. Nature Communications, Aug 2024. URL: https://doi.org/10.1038/s41467-024-50861-5, doi:10.1038/s41467-024-50861-5. This article has 9 citations and is from a highest quality peer-reviewed journal.

11. (xu2024crosstalkbetweendna pages 7-9): Jian Xu, Peiwen Fei, Dennis W. Simon, Michael J. Morowitz, Parinda A. Mehta, and Wei Du. Crosstalk between dna damage repair and metabolic regulation in hematopoietic stem cells. Cells, 13:733, Apr 2024. URL: https://doi.org/10.3390/cells13090733, doi:10.3390/cells13090733. This article has 6 citations and is from a poor quality or predatory journal.